Hospital
Brooks - TLC Hospital System, INC.
Brooks - TLC Hospital System, INC. was paid $10.97M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoBROOKS - TLC HOSPITAL SYSTEM, INC.
DUNKIRK, NY 14048
DUNKIRK, NY 14048
33aNPI1215917224assigned 01/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.97M
24GClaims250,808
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#78 of 231
Median peer was paid$561K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44 | $2K | |
| 2019 | 14,590 | $501K | |
| 2020 | 44,446 | $1.50M | |
| 2021 | 55,181 | $1.96M | |
| 2022 | 34,271 | $1.69M | |
| 2023 | 57,148 | $3.31M | |
| 2024incomplete | 45,128 | $2.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 19,535 | 18,039 | $3.21M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 4,859 | 4,490 | $1.13M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10.0% | 6,150 | 5,778 | $1.10M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.3% | 5,631 | 1,662 | $476K |
| 80053 | Comprehensive metabolic panel | 4.0% | 20,765 | 19,146 | $437K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.4% | 3,274 | 2,767 | $377K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 1,263 | 1,242 | $327K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 1,244 | 1,225 | $314K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.8% | 2,065 | 2,021 | $303K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 1,261 | 1,242 | $226K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 1,537 | 1,499 | $200K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,213 | 1,191 | $197K |
163 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 1,481 | $179K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 769 | $173K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,214 | $153K |
| 81025 | 1.3% | 3,345 | $143K | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 1,115 | $142K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 315 | $123K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 672 | $118K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,387 | $103K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,636 | $100K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,400 | $95K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 396 | $85K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,472 | $84K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,278 | $63K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,327 | $53K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,502 | $53K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,006 | $49K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,999 | $44K |
| 80061 | Lipid panel | <1% | 7,169 | $44K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,386 | $42K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 923 | $39K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 954 | $30K |
| 87390 | <1% | 1,367 | $30K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,178 | $29K |
| 86850 | <1% | 1,201 | $29K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 348 | $27K |
| 84439 | <1% | 3,302 | $26K | |
| 97161 | <1% | 265 | $24K | |
| 83880 | <1% | 886 | $23K | |
| 82607 | <1% | 1,996 | $22K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,743 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,467 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 593 | $20K |
| 84153 | <1% | 1,093 | $19K | |
| 82728 | <1% | 1,488 | $19K | |
| 82803 | <1% | 814 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,016 | $18K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 954 | $18K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 425 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 339 | $16K |
| 82746 | <1% | 1,391 | $15K | |
| 86901 | <1% | 1,246 | $15K | |
| 59025 | Fetal non-stress test | <1% | 657 | $13K |
| 86900 | <1% | 1,246 | $13K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 636 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,578 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 505 | $10K |
| 86803 | <1% | 1,150 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,100 | $10K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 26 | $9K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 75 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 976 | $8K |
| 83655 | <1% | 639 | $8K | |
| 73630 | <1% | 997 | $8K | |
| 85610 | <1% | 2,944 | $7K | |
| 97010 | <1% | 447 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,180 | $7K |
| 97162 | <1% | 65 | $7K | |
| 83540 | <1% | 1,521 | $7K | |
| 87186 | <1% | 1,572 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,833 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 24 | $7K |
| 76641 | <1% | 243 | $6K | |
| 81003 | <1% | 8,597 | $6K | |
| 83550 | <1% | 1,209 | $6K | |
| 73030 | <1% | 741 | $6K | |
| 84702 | <1% | 844 | $6K | |
| 74018 | <1% | 1,248 | $6K | |
| 12001 | <1% | 12 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 107 | $5K |
| 86140 | <1% | 1,463 | $5K | |
| 82570 | <1% | 1,102 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 152 | $5K |
| 72100 | <1% | 493 | $4K | |
| 87070 | <1% | 618 | $4K | |
| 87088 | <1% | 904 | $4K | |
| 73562 | <1% | 430 | $4K | |
| 83735 | <1% | 2,147 | $4K | |
| 73610 | <1% | 733 | $4K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 60 | $3K |
| 82043 | <1% | 712 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,720 | $3K |
| 82784 | <1% | 318 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $3K |
| 84703 | <1% | 1,202 | $3K | |
| 76801 | <1% | 38 | $3K | |
| 85652 | <1% | 1,634 | $3K | |
| 82550 | <1% | 1,067 | $3K | |
| 73130 | <1% | 572 | $3K | |
| 73564 | <1% | 248 | $2K | |
| 85730 | <1% | 1,425 | $2K | |
| 72110 | <1% | 167 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 31 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 28 | $2K |
| 90715 | <1% | 116 | $2K | |
| 84403 | <1% | 92 | $2K | |
| 86038 | <1% | 411 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $2K |
| 94726 | <1% | 41 | $2K | |
| 86762 | <1% | 157 | $2K | |
| 71271 | <1% | 77 | $2K | |
| 83690 | <1% | 2,650 | $2K | |
| 87077 | <1% | 182 | $2K | |
| 73110 | <1% | 283 | $1K | |
| 87340 | <1% | 156 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,696 | $1K |
| 73502 | <1% | 221 | $1K | |
| 86592 | <1% | 445 | $1K | |
| 84402 | <1% | 37 | $882.33 | |
| 87040 | <1% | 1,109 | $872.16 | |
| 87634 | <1% | 76 | $753.85 | |
| 94729 | <1% | 41 | $700.81 | |
| 82962 | <1% | 903 | $692.50 | |
| 93971 | <1% | 25 | $651.79 | |
| 82248 | <1% | 149 | $647.94 | |
| 76775 | <1% | 14 | $634.78 | |
| 84484 | <1% | 3,107 | $511.57 | |
| 84460 | <1% | 103 | $484.03 | |
| 85379 | <1% | 369 | $413.21 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,707 | $359.74 |
| 84450 | <1% | 72 | $342.56 | |
| 82247 | <1% | 78 | $328.97 | |
| 86769 | <1% | 15 | $274.90 | |
| 72040 | <1% | 25 | $203.76 | |
| 76536 | <1% | 12 | $198.00 | |
| 82950 | <1% | 39 | $190.04 | |
| 86255 | <1% | 29 | $165.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,268 | $162.13 |
| 84436 | <1% | 28 | $158.11 | |
| 86376 | <1% | 12 | $152.67 | |
| 86800 | <1% | 13 | $152.10 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 211 | $151.81 |
| 83605 | <1% | 1,315 | $149.11 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,010 | $107.53 |
| 84100 | <1% | 24 | $107.45 | |
| 86706 | <1% | 12 | $106.95 | |
| 86430 | <1% | 24 | $106.09 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 59 | $82.50 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,116 | $74.69 |
| 80076 | <1% | 12 | $69.24 | |
| 86431 | <1% | 12 | $56.93 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 153 | $54.10 |
| 84550 | <1% | 12 | $46.42 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 35 | $40.40 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 151 | $37.02 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 535 | $33.04 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 668 | $25.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 571 | $23.51 |
| 87081 | <1% | 13 | $20.80 | |
| 81015 | <1% | 12 | $17.43 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 797 | $15.83 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 80 | $10.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 101 | $10.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 844 | $9.32 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 205 | $1.50 |
| 80329 | 0% | 264 | $0.00 | |
| 96376 | 0% | 519 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 15 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 29 | $0.00 |
| 87430 | 0% | 17 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 30 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 14 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 40 | $0.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORRIS, KEN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Brooks - TLC Hospital System, INC. | Gowanda, NY | $632K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.